secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2026-06-15T12:52:21+00:00
Accession:  0001193125-26-270358
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia reports positive Phase 3 HAELO results for lonvo-z; BLA rolling submission initiated
--------------------------------------------------------------------------------

- 89% reduction (p<0.0001) in monthly attacks requiring on-demand treatment vs placebo; 91% reduction in moderate/severe attacks.
- 62% of lonvo-z patients attack-free and therapy-free during weeks 5-28 vs 11% placebo (p<0.0001).
- AE-QoL total score improved by -17.04 points vs placebo (p<0.0001); all TEAEs mild/moderate, no serious events in lonvo-z arm.
- Rolling BLA submission started April 2026; company expects FDA approval and U.S. launch in first half 2027.
- All patients in lonvo-z arm experienced attack-rate reductions; plasma kallikrein levels stable through Feb 2026 cutoff.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/0001193125-26-270358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/ntla-20260613.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-270358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer